CO2020006523A2 - Compuestos moduladores de sting y métodos de elaboración y uso - Google Patents

Compuestos moduladores de sting y métodos de elaboración y uso

Info

Publication number
CO2020006523A2
CO2020006523A2 CONC2020/0006523A CO2020006523A CO2020006523A2 CO 2020006523 A2 CO2020006523 A2 CO 2020006523A2 CO 2020006523 A CO2020006523 A CO 2020006523A CO 2020006523 A2 CO2020006523 A2 CO 2020006523A2
Authority
CO
Colombia
Prior art keywords
methods
manufacture
sting
modulating compounds
sting modulating
Prior art date
Application number
CONC2020/0006523A
Other languages
English (en)
Inventor
Stepan Vyskocil
Jeffrey Ciavarri
Alexandra E Gould
Paul Greenspan
Yongbo Hu
Courtney Cullis
Dylan Bradley England
Steven Langston
Gang Li
Hirotake Mizutani
Masanori Okaniwa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2020006523A2 publication Critical patent/CO2020006523A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona moduladores/agonistas de STING y métodos de síntesis y métodos de uso para la profilaxis o el tratamiento del cáncer y otras enfermedades relacionadas con STING. La presente descripción se refiere a un compuesto representado por la Fórmula (I): donde cada símbolo es tal como se definió en la descripción, o una sal farmacéuticamente aceptable de este.
CONC2020/0006523A 2017-11-10 2020-05-28 Compuestos moduladores de sting y métodos de elaboración y uso CO2020006523A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762584559P 2017-11-10 2017-11-10
US201862718613P 2018-08-14 2018-08-14
US201862754623P 2018-11-02 2018-11-02
PCT/IB2018/058846 WO2019092660A1 (en) 2017-11-10 2018-11-09 Sting modulator compounds, and methods of making and using

Publications (1)

Publication Number Publication Date
CO2020006523A2 true CO2020006523A2 (es) 2020-08-21

Family

ID=64604678

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0006523A CO2020006523A2 (es) 2017-11-10 2020-05-28 Compuestos moduladores de sting y métodos de elaboración y uso

Country Status (18)

Country Link
US (2) US11542293B2 (es)
EP (1) EP3707151B1 (es)
JP (1) JP7195317B2 (es)
KR (1) KR20200098511A (es)
CN (1) CN111566119A (es)
AU (1) AU2018364708A1 (es)
BR (1) BR112020009126A2 (es)
CA (1) CA3082351A1 (es)
CL (1) CL2020001234A1 (es)
CO (1) CO2020006523A2 (es)
EC (1) ECSP20029790A (es)
IL (1) IL274570A (es)
MX (1) MX2020004858A (es)
PE (1) PE20210156A1 (es)
PH (1) PH12020550585A1 (es)
SG (1) SG11202004113VA (es)
TW (1) TW201922263A (es)
WO (1) WO2019092660A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
WO2020092127A1 (en) 2018-10-29 2020-05-07 Venenum Biodesign, LLC Novel sting agonists
IL287938B2 (en) * 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
WO2021252904A1 (en) * 2020-06-11 2021-12-16 Massachusetts Institute Of Technology Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
CN116490244A (zh) * 2020-11-18 2023-07-25 武田药品工业株式会社 Sting激动剂、检查点抑制剂和辐射的施用
EP4413015A1 (en) * 2021-10-05 2024-08-14 Sanegene Bio USA Inc. Polyhydroxylated cyclopentane derivatives and methods of use
CN117362361A (zh) * 2023-10-09 2024-01-09 广东省农业科学院蚕业与农产品加工研究所 一种食品中呈味核苷酸二钠的检测方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
JPWO2005005450A1 (ja) 2003-07-15 2006-08-24 三井化学株式会社 環状ビスジヌクレオチドの合成方法
AU2004275696B2 (en) 2003-07-28 2010-02-18 Karagen Pharmaceuticals, Inc. Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US20090012038A1 (en) 2004-10-18 2009-01-08 Spormann Alfred M Methods for microbial biofilm destruction and interference with microbial cellular physiology
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
US20120178710A1 (en) 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2014109256A1 (ja) 2013-01-09 2014-07-17 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
CR20160564A (es) * 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
WO2017011444A1 (en) 2015-07-13 2017-01-19 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating b cell cancers
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
US20170146519A1 (en) 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
KR102789862B1 (ko) 2016-01-11 2025-04-03 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
US20190105282A1 (en) 2016-03-23 2019-04-11 Che-Ming Jack Hu Thin-shell polymeric nanoparticles and uses thereof
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
EP3448393A1 (en) 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN109715202A (zh) 2016-07-15 2019-05-03 斯必乐维生物科学公司 用于治疗疾病的化合物、组合物和方法
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
PT3523287T (pt) 2016-10-04 2021-10-06 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting
US11001605B2 (en) 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
WO2018118665A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
WO2018119117A1 (en) 2016-12-22 2018-06-28 The Regents Of The University Of California Methods of producing cyclic dinucleotides
CN110234403A (zh) 2017-01-27 2019-09-13 詹森生物科技公司 作为sting激动剂的环状二核苷酸
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018156625A1 (en) 2017-02-21 2018-08-30 Board Of Regents,The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
CN106667914B (zh) 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
KR102812783B1 (ko) 2017-08-31 2025-05-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
SG11202002218VA (en) 2017-09-15 2020-04-29 Aduro Biotech Inc Pyrazolopyrimidinone compounds and uses thereof
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
WO2019180683A1 (en) 2018-03-23 2019-09-26 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
IL287938B2 (en) 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
TW202116330A (zh) 2019-07-09 2021-05-01 日商武田藥品工業股份有限公司 Sting 促效劑及檢查點抑制劑之投與
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates

Also Published As

Publication number Publication date
JP2021502383A (ja) 2021-01-28
AU2018364708A1 (en) 2020-05-21
PE20210156A1 (es) 2021-01-26
US20210171565A1 (en) 2021-06-10
US12054512B2 (en) 2024-08-06
CL2020001234A1 (es) 2020-12-04
ECSP20029790A (es) 2020-09-30
EP3707151B1 (en) 2022-01-05
CA3082351A1 (en) 2019-05-16
PH12020550585A1 (en) 2021-04-19
US11542293B2 (en) 2023-01-03
SG11202004113VA (en) 2020-06-29
WO2019092660A1 (en) 2019-05-16
KR20200098511A (ko) 2020-08-20
CN111566119A (zh) 2020-08-21
IL274570A (en) 2020-06-30
TW201922263A (zh) 2019-06-16
US20240209017A1 (en) 2024-06-27
EP3707151A1 (en) 2020-09-16
MX2020004858A (es) 2020-10-01
JP7195317B2 (ja) 2022-12-23
BR112020009126A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2019004034A2 (es) Compuesto de piridina
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201791094A1 (ru) Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
CR20130051A (es) Promotores de apoptosis de n-acilsulfonamidas
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
AR103680A1 (es) Inhibidores selectivos de bace1
MX2021005877A (es) Compuesto heterociclico.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
NI201800071A (es) Compuestos de isoindol
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
UY37502A (es) Dinucleótido cíclico
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2019006517A (es) Moduladores de ror gamma (rorv).
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano